Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408318 | 1.00 | MAPT (0.48) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL4362884 | 0.87 | MEN1 (0.45) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL30135030 | 0.87 | MEN1 (0.45) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL8609293 | 0.84 | MAPT (0.51) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL8113158 | 0.83 | CYP19A1 (0.54) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL1302147 | 0.82 | TTR (0.49) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL9526847 | 0.81 | HSPB1 (0.51) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL29683621 | 0.80 | HSPB1 (0.49) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL16959982 | 0.80 | MAPT (0.48) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL2089645 | 0.80 | GPR35 (0.51) | MAPTMEN1KMT2AHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3969439-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020230134-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| US-8362010-B2 | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-01-29 | — | — | US | disclosed |
| CN-102459199-A | Is suitable for treating 5-hydroxytryptamine 5-HT6Benzenesulfonanilide compounds for receptor-modulated disorders | ABBOTT GMBH & CO KG | 2012-05-16 | — | — | CN | disclosed |
| WO-2011163279-A3 | LOW-POWER WIRELESSLY-LINKED RFID TRACKING SYSTEM | ROSE MARK D (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2432770-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2217583-B1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-11-30 | — | — | EP | disclosed |
| US-20110086863-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20100292220-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010125136-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-7790727-B2 | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-2217583-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090131452-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-05-21 | — | — | US | disclosed |
| WO-2009056632-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-05-07 | — | — | WO | disclosed |
| US-6071927-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-06-06 | — | — | US | disclosed |
| CN-1223656-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME (GB) | 1999-07-21 | — | — | CN | disclosed |
| EP-0052473-B1 | N-SUBSTITUTED PHENYL-1-METHYLCYCLOPROPANECARBOXAMIDES, THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-08-22 | — | — | EP | disclosed |
| US-4447260-A | N-Substituted phenyl-1-methylcyclopropanecarboxamides, and their herbicidal use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-05-08 | — | — | US | disclosed |
| EP-0052473-A2 | N-Substituted phenyl-1-methylcyclopropanecarboxamides, their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131452-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR1D, HTR1B | MAPT 4475/4885MEN1 525/4885KMT2A 2935/4885 |
| US-20110086863-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR1D, HTR1B | MAPT 4509/4885MEN1 537/4885KMT2A 2818/4885 |
| US-20100292220-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR1D, HTR4 | MAPT 4695/4885MEN1 727/4885KMT2A 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.